Join
Live feed
·
PRReleasevia Quantisnow
Denali Therapeutics Inc. logo

Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)

ByQuantisnow·Wall Street's wire, on your screen.
DNLI· Denali Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track DNLI (Denali Therapeutics Inc.) and more on Quantisnow.